营收7.13亿，同比增长15.8%！沛嘉医疗2025年报

Core Viewpoint - The company, Peijia Medical, reported revenue growth and a reduction in losses for the year ending December 31, 2025, driven by advancements in TAVR product iterations and the expansion of neurointerventional products [2][25]. Financial Performance - In 2025, the company achieved operating revenue of 713 million RMB, a year-on-year increase of 15.8%, and a gross profit of 486 million RMB, up 12.1% [4][8]. - The sales cost was 227 million RMB, resulting in a gross margin of approximately 68.2% [7]. - The net loss for the year was 208 million RMB, narrowing by 8.9% compared to the previous year [7][8]. - The neurointerventional segment generated a profit of 97 million RMB, reflecting an 86.6% year-on-year growth, while the transcatheter valve therapy segment incurred a loss of 216 million RMB, which was a 20.2% reduction from the previous year [7][8]. Product and Technology - The company has developed a multi-generation product system for transcatheter aortic valve replacement (TAVR) targeting aortic, mitral, and tricuspid valve diseases [9]. - The TAVR product line includes: - TaurusMax® (third generation) expected to be approved in 2024 and commercialized in 2025, featuring a 3D adjustable delivery system [10]. - TaurusElite® (second generation) with "retrievable and repositionable" capabilities [10]. - TaurusOne® (first generation) designed for durability and sealing [10]. - TaurusTrio® expected to be approved in 2025 for aortic regurgitation treatment [10]. - Ongoing TAVR developments include TaurusNXT® and TaurusApex®, which utilize advanced materials and technologies to enhance durability and reduce calcification risks [11][12]. Research, Business, and Market - The company increased its R&D investment to 254 million RMB, a 25.0% year-on-year growth, and has multiple products entering registration or clinical stages [18][19]. - The business model focuses on interventional consumables as the core revenue source, integrating R&D, production, and commercialization [20]. - In the domestic market, the company’s products have entered over 780 hospitals, with a TAVR implantation volume of approximately 3,900 cases, reflecting a 14.4% year-on-year increase [21]. Observations - Peijia Medical is in a phase of simultaneous commercialization and innovation pipeline development, with significant contributions from the neurointerventional business and ongoing advancements in TAVR product iterations and indications [25].